Roche Acquires Telavant, Gains Rights to Innovative Antibody (RVT-3101) for Inflammatory Bowel Disease

Roivant (Nasdaq: ROIV) announced  the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upf...

December 15, 2023 | Friday | News
Medivir Partners with Lonza for Fostrox GMP Manufacturing Campaign, Accelerating Approval Path for 2L HCC Testing and Commercialization

In addition, Lonza, Medivir's partner for process development and manufacture of drug substance, has developed a process suitable for commercial manufactur...

December 13, 2023 | Wednesday | News
South Korean Genomics Giant, Macrogen, Secures Strong Presence in Basel, Switzerland

  Macrogen Europe is seeking to expand within Switzerland from its foothold in Basel with its Sanger sequencing laborato...

December 13, 2023 | Wednesday | News
SkylineDx and VIB Initiate Joint Research Program on Immune Prediction

The significant milestone marks the first result of the company's strategic partnership2 with VIB, Flanders' leading life sciences institute, and potential...

December 11, 2023 | Monday | News
RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy CASGEVY™

RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) dedicated to developing therapies for patients w...

December 11, 2023 | Monday | News
Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics

Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium ...

December 07, 2023 | Thursday | News
Global CDMO, Vetter, Advances Sustainability with Science Based Targets Initiative (SBTi) Membership.

As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy with concrete ...

December 06, 2023 | Wednesday | News
Merck Updates on Phase III Evobrutinib Results in Relapsing MS

Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to ...

December 06, 2023 | Wednesday | News
Novartis' Fabhalta® (iptacopan) gains FDA approval as the first oral monotherapy for adults with PNH, showing superior hemoglobin improvement without transfusions.

Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inh...

December 06, 2023 | Wednesday | News
Merck Boosts Oncology Portfolio with Commercialization Agreement for Phase III Asset Pimicotinib from Abbisko

Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT) Merck to receive an exclusive commercial license ...

December 05, 2023 | Tuesday | News
IBA and University of Kansas Medical Center Collaborate on FLASH Technology Research

The two organizations published a joint abstract, “Experimental demonstration of 360nA FLASH proton beam current via synchrocyclotron using IBA Prote...

December 05, 2023 | Tuesday | News
Evaxion Reveals Innovative AI-Immunology™ Cancer Vaccine Concept

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cance...

November 28, 2023 | Tuesday | News
Spineway Expands Global Reach with VEOS Implant Rollout in Spain, Colombia, and Indonesia

Successful First Implants in Spain, Accelerating Market Penetration New Approvals in Colombia and Indonesia Boost Sales Prospects Spineway Advances as ...

November 27, 2023 | Monday | News
Fapon Accelerates the Development of its Diagnostic Ecosystem

With a steadfast dedication of 22 years to advancing the fundamental technologies of raw materials, reagent and instrument, Fapon strives to empower the gl...

November 24, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close